Atlas Trials

Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age

Clinical trial NCT02979639 · COMPLETED

Trial details

NCT number
NCT02979639
Sponsor
GlaxoSmithKline
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Herpes Zoster
Start date
2017-01-16
Primary completion
2017-04-12
Enrollment
404

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.